In the past decade, advanced lung cancer and melanoma have witnessed a surge in Food and Drug Administration (FDA)–approved treatment innovations. Yet, the impact of these advancements on ...

Erratum: Global Oncology: Tackling Disparities and Promoting Innovations in Low- and Middle-Income Countries ...

PURPOSEWe conducted a phase II, multicenter trial (ClinicalTrials.gov identifier: NCT03427866) investigating ruxolitinib administration before, during, and after allogeneic hematopoietic cell ...

An author's degree, “Megan D. Schollenberger, MD,” has been updated to “Megan D. Schollenberger, CRNP.” ...

Bladder cancer (BLCA) ranks as the tenth most common malignancy worldwide, with rising incidence and mortality rates. Owing to its molecular and clinical heterogeneity, BLCA is associated with high ...

Bladder cancer (BLCA) ranks as the tenth most common malignancy worldwide, with rising incidence and mortality rates. Owing to its molecular and clinical heterogeneity, BLCA is associated with high ...

PURPOSEIn the past decade, advanced lung cancer and melanoma have witnessed a surge in Food and Drug Administration (FDA)–approved treatment innovations. Yet, the impact of these advancements on ...

Human epidermal growth factor receptor 2 (HER2)–positive breast cancer (HER2+BC) is linked to poorer outcomes. Trastuzumab is the standard treatment, but its high cost limits access in ...

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing The following represents disclosure ...

PURPOSETo develop and validate an algorithm to extract clinically relevant data elements for prostate cancer (PCa) from prostate biopsy reports and magnetic resonance imaging (MRI) reports.PATIENTS ...

Molecular characterization of anatomically distinct urothelial carcinoma in the upper tract (UTUC) and bladder (UCB) has been challenging because of the rarity of UTUC. However, recent advances in ...